Patent ID: 8278420

Claim:
A composition for the treatment of type I diabetes in a subject, said composition comprising: a GLP-1/IgG fusion protein, wherein said GLP-1 polypeptide is selected from the group consisting of GLP-1(7-37)OH, GLP-1(7-36)amide (SEQ ID NO:1), a DPPIV resistant GLP-1 Ala 8 mutant and a DPPIV resistant GLP-1 His 7 mutant; and the IgG is human IgG2: and an autoimmune suppressor comprising at least one antigenic target epitope of a pancreatic beta-cell associated antigen for decreasing autoimmunity against islet beta cells, wherein said pancreatic beta-cell associated antigen is pre-proinsulin comprising SEQ ID NO:8, GAD65 comprising SEQ ID NO:9, 10 and/or 11, or pre-proinsulin/GAD65 (PPI/GAD65) comprising SEQ ID NO:8 and SEQ ID NO: 9, 10 and/or 11.